Viking Therapeutics (NASDAQ: VKTX) has been one of the hopefuls in a big race. The biotech company aims to launch one of the world's next big weight loss drugs. The market, on track to reach nearly $100 billion by the end of the decade, today is dominated by pharma giants Eli Lilly and Novo Nordisk, but high demand for these products means there is room for other players to succeed here too. Viking is investigating its candidate in a phase 3 trial in injectable format and is preparing to launch a phase 3 trial for its oral formulation. Earlier trial results have been positive, making Viking a potential rival for the pharma giants a few years from now.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。